Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$0.82.

  • Rhythm Pharmaceuticals' EPS (Basic) fell 1232.88% to -$0.82 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1, marking a year-over-year increase of 2840.65%. This contributed to the annual value of -$4.34 for FY2024, which is 3545.86% down from last year.
  • Rhythm Pharmaceuticals' EPS (Basic) amounted to -$0.82 in Q3 2025, which was down 1232.88% from -$0.75 recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year EPS (Basic) high stood at $0.92 for Q1 2021, and its period low was -$2.35 during Q1 2024.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.76 (2023), whereas its average is -$0.79.
  • In the last 5 years, Rhythm Pharmaceuticals' EPS (Basic) skyrocketed by 21794.87% in 2021 and then tumbled by 21413.04% in 2022.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' EPS (Basic) stood at -$1.03 in 2021, then grew by 27.83% to -$0.74 in 2022, then increased by 2.45% to -$0.72 in 2023, then fell by 1.36% to -$0.73 in 2024, then dropped by 12.07% to -$0.82 in 2025.
  • Its EPS (Basic) stands at -$0.82 for Q3 2025, versus -$0.75 for Q2 2025 and -$0.81 for Q1 2025.